EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Andreas Brandt

Work experience

1. Employer: Federal Institute for Drugs and Medical Devices (BfArM)
   - Start date: 112010
   - End date: present
   - Position: Statistical assessor
   - Activities: Statistical assessment of marketing authorisation applications, Scientific advice
   - Country: Germany
2. Employer: German Cancer Research Center (DKFZ)
   - Start date: 012007
   - End date: 102010
   - Position: PhD student, postdoctoral scientist
   - Activities: research (statistics, epidemiology)
   - Country: Germany

Education and training

1. Subject: Molecular Genetic Epidemiology
   - Start date: 012007
   - End date: 032010
   - Qualification: PhD (Dr. sc. hum.)
   - Organisation: University of Heidelberg/German Cancer Research Center (DKFZ)
   - Country: Germany
2. Subject: Mathematics
   - Start date: 102000
   - End date: 112006
   - Qualification: Dipl. Math. (MSc Mathematics equivalent)
   - Organisation: University of Bonn, University of Konstanz
   - Country: Germany

Additional information

Publications

Benda N, Brandt A. Regulatory issues with multiplicity in drug approval: Principles and controversies in a changing landscape. J Biopharm Stat. 2018;28(1):3_9

Leuchs AK, Brandt A, Zinserling J, Benda N. Disentangling estimands and the intention_to_treat principle. Pharm Stat. 2017 Jan; 16(1):12_19 Leuchs AK, Zinserling J, Brandt A,Wirtz D, Benda N. Choosing appropriate estimands in clinical trials. Therapeutic Innovation & Regulatory Science. 2015 Jul; 49(4):584_92 Chen ML, Blume H, Beuerle G, Mehta M, Potthast H, Brandt A, Schug BS, Ducharme M, Endrenyi L, Gallicano K, Schuirmann D, Welink J. Summary report of second EUFEPS/AAPS conference on global harmonization in bioequivalence. Eur J Pharm Sci. 2019 Jan;127:24_28 Brandt A, Sundquist J, Hemminki K. Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer. Ann Oncol. 2012 Jan; 23(1):251_6 Brandt A, Sundquist J, Hemminki K. Risk of incident and fatal melanoma in individuals with a family history of incident or fatal melanoma or any cancer. Br J Dermatol. 2011 Aug; 165(2):342_8 Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age_specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol. 2010 Aug; 58(2):275_80 Brandt A, Bermejo JL, Sundquist J, Hemminki K. Familial risks of breast and prostate cancers: does the definition of the at risk period matter? Eur J Cancer. 2010 Mar; 46(4):752_7 Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age of onset in familial breast cancer as background data for medical surveillance. Br J Cancer. 2010 Jan; 102(1):42_7 Brandt A, Lorenzo Bermejo J, Sundquist J, Hemminki K. Breast cancer risk in women who fulfill high_risk criteria: at what age should surveillance start? Breast Cancer Res Treat. 2010 May; 121(1):133_41 Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age at diagnosis and age at death in familial prostate cancer. Oncologist. 2009 Dec; 14(12):1209_17 Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age of onset in familial cancer. Ann Oncol. 2008 Dec; 19(12):2084_8 Hemminki K, Sundquist J, Brandt A. Incidence and mortality in epithelial ovarian cancer by family history of any cancer. Cancer. 2011 Sep 1; 117(17):3972_80 Hemminki K, Sundquist J, Brandt A. Do discordant cancers share familial susceptibility? Eur J Cancer. 2012 May; 48(8):1200_7 Hemminki K, Sundquist J, Brandt A. Familial mortality and familial incidence in cancer. J Clin Oncol. 2011 Feb 20; 29(6):712_8 Hemminki K, Mousavi SM, Sundquist J, Brandt A. Does the breast cancer age at diagnosis differ by ethnicity? A study on immigrants to Sweden. Oncologist. 2011; 16(2):146_54 Lenci RE, Bevier M, Brandt A, Bermejo JL, Sucker A, Moll I, Planelles D, Requena C, Nagore E, Hemminki K, Schadendorf D, Kumar R. Influence of genetic variants in type I interferon genes on melanoma survival and therapy. PLoS One.2012; 7(11): e50692. Roudgari H, Hemminki K, Brandt A, Sundquist J, Fallah M. Prostate cancer risk assessment model: a scoring model based on the Swedish Family_Cancer Database. J Med Genet. 2012 May; 49(5):345_52 Lenci RE, Rachakonda PS, Kubarenko AV, Weber AN, Brandt A, Gast A, Sucker A, Hemminki K, Schadendorf D, Kumar R. Integrin genes and susceptibility to human melanoma. Mutagenesis. 2012 May; 27(3):367_73 Lorenzo Bermejo J, Garcia Perez A, Brandt A, Hemminki K, Matthews AG. Comparison of six statistics of genetic association regarding their ability to discriminate between causal variants and genetically linked markers. Hum Hered. 2011; 72(2):142_52 Gast A, Bermejo JL, Claus R, Brandt A, Weires M, Weber A, Plass C, Sucker A, Hemminki K, Schadendorf D, Kumar R. Association of inherited variation in Toll_like receptor genes with malignant melanoma susceptibility and survival. PLoS One. 2011; 6(9): e24370 Shi H, Bevier M, Johansson R, Grzybowska E, Chen B, Eyfjörd JE, Hamann U, Manjer J, Enquist K, Henriksson R, Carlson J, Brandt A, Lascorz J, Butkiewicz D, Pamula_Pilat J, Tecza K, Herms S, Hoffmann P, Hemminki K, Lenner P, Försti A. Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome. Breast Cancer Res Treat. 2011 Dec;

130(3):905_16 Riihimäki M, Thomsen H, Brandt A, Sundquist J, Hemminki K. Death causes in breast cancer patients. Ann Oncol. 2012 Mar; 23(3):604_10 Riihimäki M, Thomsen H, Brandt A, Sundquist J, Hemminki K. What do prostate cancer patients die of? Oncologist. 2011; 16(2):175_81 Mousavi SM, Brandt A, Sundquist J, Hemminki K. Risks of papillary and follicular thyroid cancer among immigrants to Sweden. Int J Cancer. 2011 Nov 1; 129(9):2248_55 Mousavi SM, Brandt A, Sundquist J, Hemminki K. Esophageal cancer risk among immigrants in Sweden. Eur J Cancer Prev. 2011 Mar; 20(2):71_6 Santi I, Brandt A, Hemminki K. What is the major prognostic factor in tumor_node_metastasis staging of pancreatic adenocarcinoma? Ann Surg Oncol. 2011 Jan; 18(1):300_1 Hemminki K, Mousavi SM, Brandt A, Ji J, Sundquist J. Histology_specific risks in testicular cancer in immigrants to Sweden. Endocr Relat Cancer. 2010 Mar 8; 17(2):329_34 Hemminki K, Mousavi SM, Brandt A, Ji J, Sundquist J. Liver and gallbladder cancer in immigrants to Sweden. Eur J Cancer. 2010 Mar; 46(5):926_31 Mousavi SM, Brandt A, Weires M, Ji J, Sundquist J, Hemminki K. Cancer incidence among Iranian immigrants in Sweden and Iranian residents compared to the native Swedish population. Eur J Cancer. 2010 Feb; 46(3):599_605 Hemminki K, Ji J, Brandt A, Mousavi SM, Sundquist J. The Swedish Family_Cancer Database 2009: prospects for histology_specific and immigrant studies. Int J Cancer. 2010 May 15; 126(10):2259_67 Varadi V, Brendle A, Brandt A, Johansson R, Enquist K, Henriksson R, Svenson U, Tavelin B, Roos G, Hemminki K, Lenner P, Försti A. Polymorphisms in telomere_associated genes, breast cancer susceptibility and prognosis. Eur J Cancer. 2009 Nov; 45(17):3008_16 Brendle A, Brandt A, Johansson R, Enquist K, Hallmans G, Hemminki K, Lenner P, Försti A. Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case_control study. Eur J Cancer. 2009 Feb; 45(3):435_42 Brendle A, Lei H, Brandt A, Johansson R, Enquist K, Henriksson R, Hemminki K, Lenner P, Försti A. Polymorphisms in predicted microRNA_binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis. 2008 Jul; 29(7):1394_9 Hemminki K, Brandt A, Sundquist J, Bermejo JL. Brain cancers in siblings of salivary gland cancer patients suggest viral etiology? Int J Cancer. 2008 Mar 1; 122(5):1198_9

Projects

Memberships

Member of Methodology Working Party ESEC

Member of Biostatistics OEG

Other Relevant Information